Effect of Cannabidiol on Antiseizure Medication Cycling, Polypharmacy, and Healthcare Resource Utilisation in Patients With Dravet Syndrome, Lennox-Gastaut Syndrome, or Tuberous Sclerosis Complex: Real-World Data from a US Claims Analysis
Effect of Cannabidiol on Antiseizure Medication Cycling, Polypharmacy, and Healthcare Resource Utilisation in Patients With Dravet Syndrome, Lennox-Gastaut Syndrome, or Tuberous Sclerosis Complex: Real-World Data from a US Claims Analysis
Challenge
CBD had demonstrated ASM cycle reduction and polypharmacy benefits in controlled trials, but real-world evidence on the magnitude and sustainability of these effects in routine clinical practice was lacking.
Solution
Target RWE researchers analyzed real-world data to estimate the effect of CBD on antiseizure medication cycling, polypharmacy burden, and healthcare resource utilization in epilepsy patients, funded by Jazz Pharmaceuticals.